Global

SHERIDAN, WYOMING - December 19, 2025 - The FDA is considering awarding Commissioner's National Priority Vouchers to two investigational Merck programs-PCSK9 pill enlicitide decanoate and antibody-drug conjugate sacituzumab tirumotecan-an early signal that the agency may be willing to accelerate reviews for high-impact products even before formal filings, according to a Reuters report.

A new FDA lever that can reshape launch timing
Commissioner's National Priority Vouchers are designed to shorten the FDA's regulatory review window from the typical 10-12 months to 1-2 months. For large pharma, that time compression can meaningfully shift competitive dynamics-pulling forward commercialization, altering payer and guideline sequencing, and increasing the urgency of manufacturing readiness, launch supply, and field execution.

SHERIDAN, WYOMING - December 19, 2025 - MYTHIC, an overseas high-tech enterprise focused on anti-drone technologies, is expanding its profile as a low-altitude security provider by combining drone detection, intelligent identification, precise tracking, and efficient suppression into integrated defense systems designed for high-value, high-risk environments.

From point solutions to "intelligent airspace security barriers"
MYTHIC frames its core proposition as end-to-end protection against unauthorized UAV activity-built to perform in complex operational settings where disruption is not an option. The company says its solutions are deployed in airports, ports, petrochemical bases, hospitals, schools, luxury hotels, shopping malls, key public safety protection sites, and government office areas, reflecting buyer demand for layered protection that can be tuned to site constraints.

SHERIDAN, WYOMING - December 18, 2025 - Citroën has appointed Aline Germain as the brand's new marketing lead, effective January 1, 2026, as the automaker continues to sharpen its global positioning across electric, hybrid, and mainstream mobility segments within the Stellantis portfolio.

Leadership change signals renewed focus on brand equity and go-to-market execution
Citroën said Germain will become responsible for Marketing Citroën from 1 january 2026, replacing Federico Goyret, who has been appointed to a position to be announced later. The company said Germain will report to Citroën Brand CEO Xavier Chardon, placing the role at the center of strategy-to-market coordination as Citroën competes for attention in a crowded European and global volume market.

SHERIDAN, WYOMING - December 16, 2025 - Advita Ortho has been recognized with an Innovation award in the 2025 Medical Device Network Excellence Awards for its Newton® Balancing Technology, highlighting the growing clinical and commercial demand for more data-driven, reproducible approaches to soft-tissue management in total knee replacement surgery.

Award recognition spotlights soft-tissue balancing as a key outcomes lever
While implant design and alignment remain central to knee arthroplasty performance, soft-tissue balancing is increasingly viewed as a differentiator in patient satisfaction and functional outcomes. Advita Ortho is positioning Newton as a method to bring greater consistency to what has often been a highly surgeon-dependent step-an area the company notes has historically contributed to dissatisfaction in a meaningful share of procedures.

SHERIDAN, WYOMING - December 15, 2025 - ARIDGE has introduced new details on its next-generation A868 flying car concept and confirmed fresh progress at its flying car manufacturing plant, as the company positions two flight systems to serve different segments of China's emerging low-altitude mobility market.

Two flight systems target distinct low-altitude travel needs
ARIDGE framed the low-altitude economy as the next major growth frontier following new energy vehicles, and outlined a dual-product strategy built around different operating missions. The company is developing:

SHERIDAN, WYOMING - December 11, 2025 - A new convergence of obesity dealmaking, regulatory uncertainty at the U.S. Food and Drug Administration (FDA) and fresh neurology data out of the Clinical Trials on Alzheimer's Disease (CTAD) conference is forcing biopharma executives to recalibrate their 2026 playbooks across R&D, partnering and risk management.

Obesity Dealflow Enters a More Competitive, High-Stakes Phase

Pfizer continues to double down on cardiometabolic disease, following its $10 billion acquisition of obesity startup Metsera with an exclusive collaboration to license YaoPharma's oral GLP-1 receptor agonist YP05002. Together with other emerging oral and peptide GLP-1s, this next wave of assets is pushing obesity beyond a single-product, single-modality market and into a diversified, highly competitive landscape.

SHERIDAN, WYOMING - December 11, 2025 - Saol Therapeutics is turning an FDA rejection into a potential regulatory test case, as the biotech prepares to argue that its pyruvate dehydrogenase complex deficiency (PDCD) drug SL1009 is the ideal "poster child" for the agency's new Rare Disease Evidence Principles (RDEP) framework at a Type A meeting on December 18.

Saol Recasts a Complete Response Letter as a Strategic Opening

On September 8, Saol disclosed that the FDA had issued a complete response letter (CRL) for SL1009, an oral formulation of sodium dichloroacetate for children with PDCD, a genetic disorder affecting fewer than 1,000 people in the U.S. The CRL, according to CEO Dave Penake, "suggested that we would need to do an additional adequate and well controlled clinical trial," and that "and that's not feasible to be done by our company and in this patient population."

SHERIDAN, WYOMING - December 11, 2025 - Terns Pharmaceuticals is rapidly emerging as a serious contender in chronic myeloid leukemia (CML), after early clinical data for its allosteric BCR/ABL1 inhibitor TERN-701 more than doubled response rates seen with Novartis' approved STAMP inhibitor Scemblix in comparable settings and sent the biotech's share price sharply higher.

Best-in-Disease Early Efficacy Raises the Bar in CML

At the American Society of Hematology (ASH) annual meeting, Terns reported Phase I data from the CARDINAL trial in previously treated CML patients, with 38 participants evaluable for efficacy. TERN-701 achieved a major molecular response (MMR) rate of 75% at week 24, with 64% of patients reaching MMR overall in the dataset presented. The investigational agent also supported simple once-daily dosing without a food effect, improving convenience relative to many existing tyrosine kinase inhibitor (TKI) regimens.

SHERIDAN, WYOMING - December 10, 2025 - Pfizer Inc. is expanding its cardiometabolic ambitions through an exclusive global collaboration and license agreement with YaoPharma, a subsidiary of Shanghai Fosun Pharmaceutical, to develop, manufacture and commercialize YP05002, an oral GLP-1 receptor agonist currently in Phase 1 for chronic weight management. The deal strengthens Pfizer's position in the fast-moving obesity field and adds a differentiated small-molecule asset to its portfolio of metabolic disease candidates.

Strategic Bet on Small-Molecule GLP-1 in Obesity

Under the agreement, China-based YaoPharma will complete an ongoing Phase 1 study of YP05002 before transferring global development and commercialization rights to Pfizer. For Pfizer, the asset fits neatly into a strategy that aims to pair novel mechanisms with scalable, oral delivery formats for obesity and adjacent cardiometabolic conditions.

SHERIDAN, WYOMING - December 10, 2025 - Pfizer Inc. is setting the stage for its next financial chapter with an analyst conference call and webcast on December 16, 2025, where the U.S.-based biopharmaceutical leader will present full-year 2026 financial guidance to investors and the broader market. The event underscores how large pharma companies use structured guidance cycles to frame expectations around revenue, R&D investment, pipeline execution and capital allocation.

Anchoring Investor Expectations with 2026 Guidance

Pfizer will host the live call with investment analysts at 8:00 a.m. EST on Tuesday, December 16, 2025, with a simultaneous webcast for global stakeholders. The primary objective is to provide formal full-year 2026 financial guidance, giving clarity on topline trends, margin expectations, R&D spending and the company's capital deployment priorities.